CervoMed vs Serina Therapeutics
CRVO and SER side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVO and SER compare
Serina Therapeutics is the larger company, worth 1.4 times as much as CervoMed ($36.1M against $25.2M).
CervoMed scores higher on the StockData Score (5 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVO | SER |
|---|---|---|
| Size and price | ||
| Market cap | $25.2M | $36.1M |
| Share price | $1.67 | $1.42 |
| Change, 1 year | −77.0% | −63.8% |
| Change, 5 years | −94.3% | −94.4% |
| Beta (5Y) | 3.26 | 1.45 |
| Employees | 15 | 16 |
| StockData Score | ||
| Total score | 5 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 76.2× | – |
| P/B | 1.1× | – |
| FCF yield | – | −58.8% |
| Growth | ||
| Revenue growth (TTM) | −95.7% | – |
| Revenue growth, 5Y average | – | −18.5% |
| Profitability | ||
| Operating margin | −9407% | – |
| Net margin | −9161% | – |
| Return on equity | −108% (better) | −1175% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | – | 6.65 |
| Altman Z-score | −4.99 | −0.12 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.6% | 5.5% |
| Held by insiders | 36.9% | 49.7% |
| Insider net buying, 12 months | $3.0M (better) | −$232K |
| Short interest, % of float | 12.7% | 0.37% |
Go deeper
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
- SER stock overview
- SER income statement
- SER valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.